Cargando…

The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

INTRODUCTION: Nintedanib can inhibit processes involved in the progression of fibrosis and can reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) and fibrotic-interstitial lung disease (fibrotic-ILDs). Although the adverse events associated with nintedan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chao-Hsien, Lin, Hui-Chuan, Wang, Ya-Hui, Wang, Cheng-Yi, Lin, You Shuei, Lai, Chih-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121296/ https://www.ncbi.nlm.nih.gov/pubmed/33989328 http://dx.doi.org/10.1371/journal.pone.0251636

Ejemplares similares

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease
por: Schmid, Ulrike, et al.
Publicado: (2021)

Efficacy and Safety of Nintedanib in Patients with Interstitial Lung Disease with or without Systemic Sclerosis: A Meta-Analysis
por: Lee, Young Ho, et al.
Publicado: (2023)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Correction to: Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
por: Cottin, Vincent, et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study
por: Liang, Junyu, et al.
Publicado: (2021)

Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
por: Campochiaro, Corrado, et al.
Publicado: (2023)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
por: Wang, Li-Ting, et al.
Publicado: (2021)

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
por: Toellner, Hannah, et al.
Publicado: (2017)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
por: Vacchi, Caterina, et al.
Publicado: (2020)

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
por: Westerink, Lotte, et al.
Publicado: (2022)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Premorbid use of selective beta-blockers improves sepsis incidence and course: Human cohort and animal model studies
por: Hong, Shiao-Ya, et al.
Publicado: (2023)

Safety of nintedanib before lung transplant: an Italian case series
por: Balestro, Elisabetta, et al.
Publicado: (2018)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
por: Sumi, Toshiyuki, et al.
Publicado: (2021)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
por: Wang, Cheng-Yi, et al.
Publicado: (2019)

Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis–associated interstitial lung disease mice
por: Mikami, Shintaro, et al.
Publicado: (2022)

A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
por: Kakuwa, Tamaki, et al.
Publicado: (2018)

The Association between the Risk of Aortic Aneurysm/Aortic Dissection and the Use of Fluroquinolones: A Systematic Review and Meta-Analysis
por: Lai, Chih-Cheng, et al.
Publicado: (2021)

Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug
por: Kafle, Sunam, et al.
Publicado: (2021)

Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model
por: Miura, Yoko, et al.
Publicado: (2021)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
por: Urushiyama, Hirokazu, et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
por: Boutel, Maria, et al.
Publicado: (2023)

The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials
por: Lin, Wei-Ting, et al.
Publicado: (2021)

The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies
por: Yanagihara, Toyoshi, et al.
Publicado: (2020)

Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases
por: Nakashima, Kazuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t0c36i7c5ojj0r2rga250l2k1h